Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 27 Aug 2026

Reading PSA Trends During Lu-177 PSMA Therapy

Your PSA number during Lu-177 PSMA therapy tells part of the story - but only part. This guide explains what PSA50 response means, why an early rise is not always bad news, and how to read PSA trends alongside imaging.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 27 Aug 2026
Reading PSA Trends During Lu-177 PSMA Therapy

This article is for men with metastatic castration-resistant prostate cancer (mCRPC) who are receiving - or considering - lutetium Lu-177 vipivotide tetraxetan, sold under the brand name Pluvicto. One question your care team tracks closely during every cycle is what your PSA is doing. The answer matters, but it's more complex than just checking if it's rising or falling.

PSA stands for prostate-specific antigen. It's a protein produced mainly by prostate cells, and it's measured with a routine blood test. During Lu-177 PSMA therapy, PSA trends are used as one marker of how the cancer is responding. But those trends can be harder to read than you might expect. An early rise isn't always bad news. A decline is encouraging but not the whole picture. This guide explains what to look for and what questions to ask.

Why does PSA matter during radioligand therapy?

Prostate cancer cells produce PSA. When the cancer grows or spreads, PSA in the blood tends to rise. When treatment slows or shrinks the cancer, PSA tends to fall. This is why oncologists measure it before each cycle of Lu-177 PSMA therapy and sometimes between cycles.

PSA isn't a perfect marker. It can fluctuate because of inflammation, the rapid breakdown of cancer cells caused by radiation, or normal day-to-day variation. A single reading tells you less than the trend over several measurements. Your care team looks at the direction and pace of change - not just the number on a given day.

The Prostate Cancer Foundation describes PSA as a key monitoring tool during Lu-177 PSMA therapy, used alongside imaging to assess how treatment is affecting the cancer over time.

What is a PSA50 response and why does it matter?

The most widely used benchmark in clinical trials is a PSA50 response - a fall in PSA of at least 50% from the level at the start of treatment. Reaching this threshold is associated with better outcomes and gives your team one of its clearest signals that treatment is working.

In the REALITY study - a large prospective registry of patients receiving Lu-177 PSMA therapy - approximately 52% of patients achieved a PSA decline of at least 50%, according to a registry analysis published in the European Journal of Nuclear Medicine and Molecular Imaging. The rate varies across studies, depending on prior treatment history, disease burden, and how much PSMA the cancer expresses.

A long-term outcomes study of patients treated with Lu-177 PSMA-617 found that patients who achieved a PSA decline of at least 50% had a median overall survival of 18.4 months, compared with 13.3 months for the overall study population. A post-hoc analysis of the phase 3 VISION trial confirmed that the magnitude of PSA decline was associated with improvements in survival and patient-reported quality of life in men receiving lutetium Lu-177 vipivotide tetraxetan plus standard of care.

A PSA50 response doesn't guarantee a specific outcome, and missing it doesn't mean treatment has failed. But it's one of the clearest signals your team has that the approach is working, and it may shape decisions about continuing or adjusting treatment after a set number of cycles.

Why does PSA sometimes rise first?

Watching your PSA go up early in treatment is unsettling. This happens more often than many patients expect, and it has a specific explanation.

A temporary rise in PSA - sometimes called a PSA flare - can occur after the first one or two cycles of Lu-177 PSMA therapy. The radiation delivered by the lutetium payload causes rapid breakdown of cancer cells. As those cells die, they release stored PSA into the bloodstream, causing a temporary spike. This doesn't necessarily mean the cancer is growing. In some patients, a flare in the first four to eight weeks is followed by a real and sustained PSA decline in later cycles.

For a detailed explanation of what a PSA flare looks like and how your team interprets it, read PSA Flare After First Lu-177 PSMA Injection Explained. The key point: don't make treatment decisions based on a single PSA result in the first few weeks. Your team needs the trend across multiple readings, not just one number.

PSA is one signal, not the whole picture

PSA is useful, but it doesn't capture everything happening in your body. In some patients, tumors may be shrinking - visible on imaging - while PSA hasn't yet changed. In other cases, PSA may stabilize while new activity appears in a small number of lesions on a scan. This gap between PSA and imaging is called a discordant response.

Research suggests that measuring tumor PSMA expression through imaging may better predict survival after radioligand therapy than PSA change alone in some situations. A study on imaging-based response assessment in mCRPC patients receiving Lu-177 PSMA therapy found that imaging-derived measures of tumor burden were stronger predictors of progression-free survival than PSA-based measures in several clinical settings.

Because of this, specialist centers use both PSA monitoring and imaging - typically a PSMA-PET scan alongside CT or bone scan - at regular intervals during treatment. Understanding what your PSMA-PET results mean for Lu-177 eligibility and response gives you the tools to interpret scan findings alongside PSA numbers as a more complete picture.

The Society of Nuclear Medicine and Molecular Imaging has published guidance on post-treatment imaging for patients receiving Lu-177, recommending a combined approach to response assessment that goes beyond PSA alone.

What if PSA keeps rising despite treatment?

If PSA continues to rise across two or more cycles - and imaging confirms active disease - it may mean the cancer isn't responding adequately to Lu-177 PSMA therapy. There are several possible reasons.

Some tumors express lower levels of PSMA, which limits how much of the radioactive payload reaches them. In other cases, parts of the cancer may shift toward a PSMA-negative state over time, making them harder to target with this approach. There may also be disease sites that produce PSA but aren't PSMA-positive - driving the number upward without being affected by the radioligand.

A persistent PSA rise is a prompt for a careful conversation with your team. Your oncologist will assess the imaging, compare current scans with earlier ones, and weigh whether to continue, modify, or change the treatment approach. For a fuller picture of what may come next in this situation, see Lu-177 PSMA Resistance and Next Steps for mCRPC.

If you want an independent view of your PSA trend or your team's interpretation of your case, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you (and what alternatives exist if not) - including a review of your recent PSA results and imaging reports.

How often will your PSA be checked?

The exact schedule varies by center, but a common pattern is:

  • A baseline PSA before the first cycle
  • A PSA check before each subsequent cycle (typically spaced six weeks apart)
  • Additional checks between cycles if PSA changed significantly at the last reading
  • A post-treatment PSA check four to six weeks after the final cycle

The six-week spacing between cycles is deliberate. It gives each dose of radiation time to work and provides enough data points to distinguish a meaningful trend from normal variation. Small week-to-week fluctuations are expected and don't usually require action on their own.

Your team may also track PSA velocity - how fast the level is changing over time - and PSA doubling time - how long it takes for PSA to double. A lengthening PSA doubling time can suggest the cancer is slowing even before PSA starts to fall outright. These measures add context that a single reading can't provide.

Symptoms and PSA do not always move together

PSA response and symptom improvement don't always happen at the same time. Some patients notice reduced bone pain or improved energy before their PSA number shifts. Others see PSA fall first, with symptom relief following later. Neither pattern is more correct than the other.

Quality-of-life improvements - including pain reduction and improved physical function - have been reported in patients receiving Lu-177 PSMA therapy, and these improvements may appear independent of PSA changes. So if you feel better but the PSA hasn't moved yet, that observation is worth reporting to your team. It may reflect treatment activity that the PSA number hasn't yet captured.

Conversely, if PSA is falling but you develop new symptoms - new bone pain, significant fatigue, or unintended weight loss - tell your team without waiting for the next scheduled visit. A falling PSA doesn't guarantee that every disease site is responding equally. Your team can assess whether the clinical picture matches the biochemical trend.

Questions to ask your team about PSA and response

  • What PSA level are we starting from, and what decline would you consider meaningful for my case?
  • How many cycles will you give before deciding whether this treatment is working?
  • Will you use imaging alongside PSA to assess response, and on what schedule?
  • If my PSA rises early, how will you tell whether it's a flare or a sign of inadequate response?
  • What is my current PSA doubling time, and has it changed since treatment started?
  • If PSA doesn't respond after a full course, what would you recommend next?

When to talk to your doctor

Speak to your oncology team without waiting if your PSA rises significantly between scheduled checks, if you develop new bone pain or swelling, or if you notice a meaningful change in how you feel between cycles. Your team can help determine whether the change reflects treatment activity, a flare, or a need to reassess the plan.

If you want a specialist review of your PSA trend or a second opinion on your treatment approach, you can send your recent results and scans to the Lutetium Therapy team for a response review. If Lu-177 isn't the right fit for your case, a second opinion on alternative options is part of that conversation.

This article is for general information and isn't a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What PSA response rate can I expect from Lu-177 PSMA therapy?

In major clinical studies, roughly half of patients with mCRPC achieved a PSA decline of at least 50% - called a PSA50 response. The REALITY registry study found this in approximately 52% of patients. Your personal response depends on how much PSMA the cancer expresses, how many prior treatments you have had, and other individual factors. Some patients see smaller declines, and some see no PSA change at all. Most teams assess response after two or more full treatment cycles rather than after just one.

Is a PSA flare dangerous?

A PSA flare - a temporary rise in PSA in the first few weeks of treatment - is not the same as treatment failure. It is thought to happen because the radiation causes cancer cells to break down rapidly, releasing stored PSA into the blood. If a flare is followed by a PSA decline in subsequent cycles, it is considered a recognized part of the response pattern. A rise that continues across multiple cycles without any decline is a different situation and requires further assessment by your care team.

Can my PSA fall even if there is still active cancer present?

Yes. PSA measures a biochemical signal from prostate cancer cells, but it does not capture every tumor site equally. Some lesions may be PSMA-negative or may produce less PSA than others. A falling PSA is an encouraging sign, but imaging - including PSMA-PET and CT or bone scan - gives additional information about whether specific disease sites are responding. Your team uses both together for the most complete assessment.

How long does it take to see a PSA response to Lu-177 PSMA therapy?

Most specialist teams look for a meaningful PSA trend after two full treatment cycles, which is roughly 12 weeks from the start. An early rise in the first four to eight weeks does not rule out eventual response. Your team tracks the direction and speed of change over multiple readings rather than reacting to any single result.

What happens if Lu-177 PSMA therapy does not produce a PSA response?

If PSA continues to rise and imaging confirms progression after a full course of treatment, your oncologist will discuss next steps. Options depend on what prior treatments you have had, what the current imaging shows, and whether any clinical trials may be relevant. A second specialist opinion can help clarify what alternatives remain and whether the original plan needs adjustment.

My PSA is falling but I still have bone pain. Does that mean treatment is not working?

Not necessarily. PSA and symptom improvement do not always move in parallel, especially early in treatment. Some patients experience a temporary increase in bone pain - called a pain flare - in the first weeks of therapy even when PSA is declining. Pain flare is usually short-lived. If bone pain is new, worsening, or not improving after the first one or two cycles, report it to your care team so they can assess whether it is related to treatment activity or a separate issue.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PSA Response During Lu-177 PSMA Therapy | mCRPC | lutetium-therapy